van der Merwe Johan, Casselman Filip, Stockman Bernard, Vermeulen Yvette, Degrieck Ivan, Van Praet Frank
Department of Cardiovascular and Thoracic Surgery, OLV Clinic, Aalst, Belgium.
Department of Cardiovascular and Thoracic Surgery, OLV Clinic, Aalst, Belgium
Interact Cardiovasc Thorac Surg. 2016 Jan;22(1):13-8. doi: 10.1093/icvts/ivv281. Epub 2015 Oct 13.
This study presents the first report on short- and long-term outcomes in redo-port access surgery after previous port access surgery (redo-PAS-PAS) for new or recurrent mitral valve (MV) and tricuspid valve (TV) disease.
Our current surgical team performed redo-PAS-PAS in 26 consecutive patients who had previous port access surgery (mean age 65.8 ± 13.3 years, 46.2% female, 42.3% older than 70 years, mean logistical EuroSCORE 22.5 ± 21.6%) between 1 February 1997 and 30 June 2014. Surgical indications included among others MV prosthesis dysfunction (n = 8, 30.8%), endocarditis (n = 10, 38.5%) and TV dysfunction (n = 3, 11.5%). The mean time interval between primary PAS and redo-PAS-PAS was 70.32 ± 57.4 months.
Redo-PAS-PAS procedures included MV replacement (n = 19, 73.1%), MV repair (n = 5, 19.2%), and TV repair (n = 2, 7.7%). Sternotomy conversion was required in 5 patients (19.2%), of which 4 (15.4%) were early conversions due to lung adhesion and 1 (3.8%) due to a late intraoperative complication. The mean cardiopulmonary bypass and cross-clamp times were 163.3 ± 57.9 and 101.2 ± 43.8 min, respectively. Postoperative mechanical ventilation longer than 72 h was required in 4 patients (15.4%). In-hospital morbidities included hospital-acquired pneumonia (n = 3, 11.5%), postoperative air leaks (n = 2, 7.7%) and revision for bleeding (n = 1, 3.8%). The mean length of hospital stay was 16.1 days. Long-term clinical and echocardiographic follow-up were 48.3 ± 39.2 and 44.6 ± 32.9 months, respectively. The Kaplan-Meier analyses for survival and freedom from mitral and tricuspid valve reintervention (n = 26) at 5 years were 83.9 and 95.8%, respectively, with 91.3% of surviving patients classified as being NYHA II or less. Echocardiographic follow-up showed no residual mitral regurgitation more than grade I in all redo mitral valve repairs and no paravalvular leak post-valve replacement.
Redo-PAS-PAS is our routine approach and we apply this strategy in the majority of patients who had previous port access surgery. The predicted procedure-related mortality, morbidities, patient satisfaction and long-term outcomes are favourable.
本研究首次报告了既往接受过端口入路手术(redo-PAS-PAS)的患者再次接受端口入路手术治疗新发或复发性二尖瓣(MV)和三尖瓣(TV)疾病的短期和长期结果。
我们当前的手术团队在1997年2月1日至2014年6月30日期间,为26例既往接受过端口入路手术的患者(平均年龄65.8±13.3岁,46.2%为女性,42.3%年龄大于70岁,平均逻辑欧洲心脏手术风险评估系统评分为22.5±21.6%)连续实施了redo-PAS-PAS手术。手术适应证包括MV人工瓣膜功能障碍(n = 8,30.8%)、心内膜炎(n = 10,38.5%)和TV功能障碍(n = 3,11.5%)。初次PAS与redo-PAS-PAS之间的平均时间间隔为70.32±57.4个月。
redo-PAS-PAS手术包括MV置换(n = 19,73.1%)、MV修复(n = 5,19.2%)和TV修复(n = 2,7.7%)。5例患者(19.2%)需要转为胸骨正中切开术,其中4例(15.4%)因肺粘连早期转为胸骨正中切开术,1例(3.8%)因术中晚期并发症转为胸骨正中切开术。平均体外循环时间和主动脉阻断时间分别为163.3±57.9分钟和101.2±43.8分钟。4例患者(15.4%)术后机械通气时间超过72小时。住院期间的并发症包括医院获得性肺炎(n = 3,11.5%)、术后气胸(n = 2,7.7%)和因出血进行的再次手术(n = 1,3.8%)。平均住院时间为16.1天。长期临床和超声心动图随访分别为48.3±39.2个月和44.6±32.9个月。5年时,26例患者的生存及二尖瓣和三尖瓣再次干预自由度的Kaplan-Meier分析结果分别为83.9%和95.8%,91.3%的存活患者纽约心脏协会心功能分级为Ⅱ级或更低。超声心动图随访显示,所有再次二尖瓣修复患者的二尖瓣反流均不超过Ⅰ级,瓣膜置换术后无瓣周漏。
redo-PAS-PAS是我们的常规方法,我们将此策略应用于大多数既往接受过端口入路手术的患者。预计与手术相关的死亡率、并发症、患者满意度和长期结果良好。